Page 348 - Programme book for The International Liver Congress 2015, EASL ILC 2015

Clinical Trials in Progress (Cont.)

P1338 AN INTERNATIONAL OBSERVATIONAL STUDYTO ASSESS
THE USE OF SORAFENIB AFTERTRANSARTERIAL
CHEMOEMBOLIZATION (TACE) IN PATIENTSWITH
HEPATOCELLULAR CARCINOMA (HCC): OPTIMIS
Markus Peck-Radosavljevic*, Jean-Luc Raoul, Han Chu Lee,
Masatoshi Kudo, Keiko Nakajima, Ann-Lii Cheng, Austria

P1339 EVALUATING THE EFFICACY AND SAFETY OF EVEROLIMUS
WITH REDUCED TACROLIMUS VERSUS STANDARD
TACROLIMUS IN LIVING DONOR LIVER TRANSPLANT
RECIPIENTS: H2307 STUDY DESIGN
C Sips*, K S. Suh, J W. Joh, T Yoshizumi, W C. Lee,Y Genyk,
E-D Martzloff, Z Wang, P Lopez, D Grant, Switzerland

P1340 ASSESSING NUTRITION THROUGH OBSERVATION IN EARLY
CIRRHOSIS OF THE LIVER: A NURSE LED PILOT STUDY
Antonella Ghezzi*, Paula Crick, Moira Taylor, Marc Abraham, Neil Guha,
Guruprasad Aithal, The United Kingdom

ePOSTERS P1341 PERFORM: AN IMAGING STUDY OF ARTERIAL BLOOD
FLOW TO LIVER METASTASES BEFORE AND AFTER
SELECTIVE INTERNAL RADIOTHERAPY
Helen S. Winter*, Esme Hill, Nigar Syed, Daniel Chung, Jamie Franklin,
Jane Statham, Jenni Lee, Nick Weir, Graeme Weir, Ewan Brown,
Jamie Mills, Suzie Anthony, Dilip Patel, Phil Boardman, Ewan Anderson,
Fergus Gleeson, Ricky Sharma, The United Kingdom

P1342 PROSPECTIVE REAL WORLD OUTCOMES STUDY OF HE
PATIENTS’ EXPERIENCE ON RIFAXIMIN-A (PROSPER):
AN OBSERVATIONAL STUDY AMONG 550 PATIENTS
Hanna Sodatonou*, Aleksander Krag, Rajiv Jalan, Peter Conway,
Jeff Pilot, Amr Radwan, The United Kingdom

YI P1343 PHASE I DOSE-ESCALATION STUDY EVALUATING
THE SAFETY AND PHARMACOKINETICS OF ORAL
ARTESUNATE IN PATIENTS WITH ADVANCED
HEPATOCELLULAR CARCINOMA (DESPARTH TRIAL)
Yves-Paul Vandewynckel*, Klara Rombauts, Xavier Verhelst, Luc Van Bortel,
Bart De Spiegeleer, Anja Geerts, Hans Van Vlierberghe, Belgium

348 The International Liver Congress™ 2015 • ILC Programme